Prospects for the use of molecular genetic markers to improve diagnostics and targeted therapy of melanoma
Автор: Khripko O.P., Khripko Yu.I., Deulin I.Yu., Koldysheva E.V., Zakharov V.N.
Журнал: Cardiometry @cardiometry
Статья в выпуске: 24, 2022 года.
Бесплатный доступ
Skin melanoma is a highly aggressive malignant neoplasm, the treatment of disseminated forms of which remains a serious problem, despite recent advances in the development of medical drugs based on the inhibition of the BRAF oncogene as well as on the basis of immune response regulators [1]. In addition, the question of identifying prognostic markers of metastasis and diagnostic markers of skin melanoma remains relevant. Despite advances in understanding the pathogenesis of melanoma and the development of various therapies aimed at immune checkpoints, the patient survival remains low in the progressing metastatic disease [2]. Targeted therapy and immune checkpoint inhibitors are used in the treatment of metastatic melanoma.
Короткий адрес: https://sciup.org/148326334
IDR: 148326334 | DOI: 10.18137/cardiometry.2022.24.conf.40
Список литературы Prospects for the use of molecular genetic markers to improve diagnostics and targeted therapy of melanoma
- Banaszynski M., Kolesar J.M. Vemurafenib and ipilimumab: new agents for metastatic melanoma. Am. J. Health Syst. Pharm. 2013; 70: 1205-102.
- Bandarchi B., Jabbari C.A., Vedadi A., Navab R. Molecular biology of normal melanocytes and melanoma cells. J. Clin. Pathol. 2013; 66:644-648.
- Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011; 364(26): 2507-2516.
- Chen G., Davies M.A. Targeted therapy resistance mechanisms and therapeutic implications in melanoma. Hematol. Oncol. Clin. North. Am. 2014; 28(3): 523-536.
- Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S. et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892): 949-954.
- Flaherty K.T., Infante J.R., Daud A., Gonzalez R., Kefford R.F., Sosman J. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012; 367(18): 1694-1703.
- Girotti M.R., Pedersen M., Sanchez-Laorden B., Viros A., Turajlic S., Niculescu-Duvaz D. et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 2013; 3(2): 158-167.
- Ribas A., Gonzalez R., Pavlick A., Hamid O., Gajewski T.F., Daud A. et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014; 15(9): 954-965.
- Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 2012;366(8): 707-714.
- Sun C., Wang L., Huang S., Heynen G.J., Prahallad A., Robert C., Haanen J. et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014; 508(7494): 118-122.
